Tag: denali therapeutics
February 15, 2019
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
Denali Therapeutics (NASDAQ: DNLI) has announced the initiation of dosing in a Phase 1b clinical study of DNL747 in patients with... December 10, 2018
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing... November 20, 2018
Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule
Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results...
November 1, 2018
Denali Therapeutics Partners with Sanofi
The companies will jointly develop RIPK1 inhibitor molecules, which could treat Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis and more. November 1, 2018
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors
Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it... October 3, 2018